

Special Issue

Inflammatory Chaos in *Helicobacter pylori* Infection

Message from the Guest Editor

Helicobacter pylori is one of the most common human pathogens and is closely associated with pathogenesis of gastritis, peptic ulcer, gastric cancer and MALT lymphoma. A total of 4.4 billion individuals are estimated to be colonized with *H. pylori*, which equals to 60% of the world population in the middle of last decade. The prevalence of *H. pylori* infection is low in developed countries and high in developing countries, ranging between 19% in Switzerland and 88% in Nigeria. The survival of the *H. pylori* in its niche, the gastric mucosa, can be attributed to the ability of this microbe to manipulate its host's immunity. *H. pylori* has evolved strategies to evade or derange innate and adaptive immune responses. This bacterium is generally detected by pattern recognition receptors (PRRs) to mount the different immune responses, whereas *H. pylori* has evolved strategies for masking the toll-like receptor (TLR) ligands to modulate the sensing which ultimately affects signaling pathways for the production of chemokines and cytokines.

Guest Editor

Dr. Suneesh Kumar Pachathundikandi

Department of Environmental Microbiology, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226025, Uttar Pradesh, India

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/193840

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).